Panacea Biotec’s Success Analyzed

Panacea Biotec, a company that makes vaccines, jumped in price by 13.25% to reach Rs 406. This happened because they won a big award from UNICEF – the United Nations’ group that helps children. UNICEF recognized Panacea Biotec for providing a special vaccine, Easyfive-TT, that meets strict standards for use worldwide.

Key Points

• UNICEF awarded Panacea Biotec for its Easyfive-TT vaccine supply.
• Contract value increased by $8.93 million (Rs 80 crore) over two years.
• New contracts add $2.55M (Rs 23 crore) for 2026 and $2.70M (Rs 24 crore) for 2027.
• Extra $3.68 million (Rs 33 crore) award for 2027 boosts overall value.
• Contract executes based on UNICEF orders, ongoing in 2026 and 2027.
• No promoter involvement with this important international vaccine agreement.

What Does This Mean?

This award is fantastic news for Panacea Biotec. It means they’re doing a good job making vaccines that countries around the world need. UNICEF is trusting them to supply a vital vaccine, which will help protect many children from serious diseases.

Financial Update

It’s important to note that Panacea Biotec had a difficult quarter financially. They reported a loss and their sales went down. However, this award could change things, as it provides them with a huge new supply agreement.

About Panacea Biotec

Panacea Biotec is a company focused on creating and selling vaccines. They do this in India and in other countries too. They invest a lot of money in research and development to make new and better vaccines.

Looking Ahead

Panacea Biotec will now be working with UNICEF to deliver the vaccine. UNICEF will let everyone know exactly how much they’re paying and when the vaccine will be sent. This contract is expected to continue through 2026 and 2027.

The company’s significant contract with UNICEF represents a major step toward bolstering global child health initiatives.